Advertisement

Overview of Cervical and Anal Cytopathology

  • Xinmin ZhangEmail author
  • Kathriel Brister
Chapter
Part of the Practical Anatomic Pathology book series (PAP)

Abstract

Pap test has been an excellent example of success in medicine because of its role in remarkably reducing the incidence and death rate of cervical cancer. However, it is not a perfect test, and to certain degree, it became the victim of its success due to overexpectation of the public that led to a stringent government regulation of the practice. With the evolving of our knowledge of high-risk HPV infection in the development of cervical cancer, HPV molecular tests have been developed to enhance the Pap test in the early detection of cervical cancer. HPV vaccination has further advanced the battle against the development of cervical cancer by blocking the initial viral infection. This chapter briefly updates the current status of cervical cancer prevention and early detection, and the government regulation on pertinent cytology practice. Anal smear has recently emerged as a new approach to detect anal epithelial dysplastic changes; common questions in daily anal-rectal cytology are also discussed.

Keywords

Pap smear Dysplasia HPV infection HPV test Anal-rectal cytology Bethesda system CLIA 88 

References

  1. 1.
    Vilos EA. The history of the Papanicolaou smear and the odyssey of George and Andromace Papanicolaou. Obstet Gynecol. 1998;91:479–83.CrossRefPubMedGoogle Scholar
  2. 2.
    Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol. 1941;42:193–26.CrossRefGoogle Scholar
  3. 3.
    Limaye A, Connor AJ, Huang X, Luff R. Comparative analysis of conventional Papanicolaou tests and a fluid-based thin-layer method. Arch Pathol Lab Med. 2003;127:200–4.PubMedGoogle Scholar
  4. 4.
    Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol. 2008;111:167–77.CrossRefPubMedGoogle Scholar
  5. 5.
    Siebers AG, Klinkhamer PJ, Grefte JM, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA. 2009;302:1757–64.CrossRefPubMedGoogle Scholar
  6. 6.
    Biscotti CV, Dawson AE, Dziura B, et al. Assisted primary screening using the automated ThinPrep Imaging System. Am J Clin Pathol. 2005;123:281–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Lee JSJ, Kuan L, Seho O, Patten FW, Wilbur DC. A feasibility study of the AutoPap System location-guided screening. Acta Cytol. 1998;42:221–6.CrossRefPubMedGoogle Scholar
  8. 8.
    NIH Fact Sheets - Cervical Cancer. March 29, 2013. https://report.nih.gov/NIHfactsheets/ViewFactSheet.aspx?csid=76.
  9. 9.
    Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systemic review. Ann Intern Med. 2000;132:810–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Renshaw AA, DiNisco SA, Minter LJ, Cibas ES. A more accurate measure of the false-negative rate of Papanicolaou smear screening is obtained by determining the false-negative rate of the rescreening process. Cancer. 1997;81:272–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Mount S, Harmon M, Eltabbakh G, Uyar D, Leiman G. False positive diagnosis in conventional and liquid-based cervical specimens. Acta Cytol. 2004;40:438–42.Google Scholar
  12. 12.
    National Cancer Institute. HPV and Cancer. Acta Cytol. 2004;48:​363–71. https://www.cancer.gov/about-cancer/causes-prevention/​risk/​infectious-agents/hpv-and-cancer.
  13. 13.
    Choi YJ, Park JS. Clinical significance of human papillomavirus genotyping. J Gynecol Oncol. 2016;27:e21.CrossRefPubMedGoogle Scholar
  14. 14.
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Arbyn M, Ronco G, Anttila A, Meijer CJ, Polijak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30 Suppl 5:F88–99.CrossRefPubMedGoogle Scholar
  16. 16.
    Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijers PJF, Arbyn M, Kitchener H, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomized controlled trials. Lancet. 2014;383:524–32.CrossRefPubMedGoogle Scholar
  17. 17.
    Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, Kinney WK, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015;132:178–82.CrossRefGoogle Scholar
  18. 18.
    Boers A, Slagter-Menkema L, van Hemel BM, Belinson JL, Ruitenbeek T, Buikema HJ, Klip H, et al. Comparing the Cervista HPV test and Hybrid Capture 2 assay in a Dutch screening population: Improved specificity of the Cervista HPV test by changing the cut-off. PLoS One. 2014;9:e101930.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Johnson LR, Starkey CR, Plamer J, Taylor J, Stout A, Holt S, Hendren R, et al. A comparison of two methods to determine the presence of high-risk HPV cervical infections. Am J Clin Pathol. 2008;130:401–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Bartholomew DA, Luff RD, Quigley NB, Curtis M, Olson MC. Analytical performance of Cervista HPV 16/18 genotyping test for cervical cytology samples. J Clin Virol. 2011;51:38–43.CrossRefPubMedGoogle Scholar
  21. 21.
    Einstein MH, Martens MG, Garcis FAR, Ferris DG, Mitchell AL, Day SP, Olson MC. Clinical validation of the Cervista HPV HR 16/18 genotyping tests for use in women with ASC-US cytology. Gyneco Oncol. 2010;11:116–22.CrossRefGoogle Scholar
  22. 22.
    Poljak M, Ostrbenk A. The Abbott RealTime high risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies. Acta Dermatovenerol Alp Pannonica Adriat. 2013;22:43–7.PubMedGoogle Scholar
  23. 23.
    Phillips S, Garland SM, tan JH, Quinn MA, Tabrizi SN. Comparison of the Roche Cobas 4800 HPV assay to Digene Hybrid Capture 2, Roche linear array and Roche amplicor for detection of high-risk human papillomavirus genotypes in women undergoing treatment for cervical dysplasia. J Clin Virol. 2015;62:63–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Levi AW, Bernstein JI, Hui P, Duch K, Schofield CDC. A comparison of the Roche Cobas HPV test with the Hybrid Capture 2 test for the detection of high-risk human papillomavirus genotypes. Arch Pathol Lab Med. 2016;140:153–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Dockter J, Schroder A, Eaton B, Wang ASikhamsay N, Morales L, Giachetti C. Analytical characterization of the APTIMA HPV assay. J Clin Virol. 2009;45(Suppl 1):S39–47.CrossRefPubMedGoogle Scholar
  26. 26.
    Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, Gadag V, et al. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 assay but more specific at detecting cervical precancer and caner. J Clin Microbiol. 2011;49:557–64.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Tjalma WAA, Depuydt CE. Don’t forget HPV-45 in cervical cancer screening. Am J Clin Pathol. 2012;137:161–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Castle PE, Cuzick J, Stoler MH, Wright TC Jr, Reid JL, Dockter J, Giachetti C, et al. Detection of human papillomavirus 16, 18 and 45 in women with ASC-US cytology and the risk of cervical precancer. Results from the CLEAR HPV study. Am J Clin Pathol. 2015;143:160–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645–51.CrossRefPubMedGoogle Scholar
  30. 30.
    Schiller JT, Castellsague X, Graland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30:F123–38.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Thomas TL. Cancer prevention: HPV vaccination. Semin Oncol Nurs. 2016;32:273–80.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Valentino K, Poronsky CB. Human papillomavirus infection and vaccination. J Pediatr Nurs. 2016;31:e155–66.CrossRefPubMedGoogle Scholar
  33. 33.
    El-Zein M, Richardson L, Franco EL. Cervical cancer screening of HPV vaccinated populations: cytology, molecular testing, both or none. J Clin Virol. 2016;76:S62–8.CrossRefPubMedGoogle Scholar
  34. 34.
    American Cancer Society Recommendations for Human Papillomavirus (HPV) Vaccine Use. American Cancer Society. Website https://www.cancer.org/cancer/cancer-causes/infectious-agents/hpv/acs-recommendations-for-hpv-vaccine-use.html. Last Medical Review: 19 July 2016.
  35. 35.
    Evidence based recommendations on Human Papilloma Virus (HPV) Vaccines schedules. March 11, 2014 WHO Website: https://www.who.int/immunization/sage/meetings/2014/april/1_HPV_Evidence_based_recommendationsWHO_with_Appendices2_3.pdf.
  36. 36.
    Bosch FX, Robles c DM, Arbyn M, Baussano I, Clavel C, Ronco G, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol. 2016;13:119–32.CrossRefPubMedGoogle Scholar
  37. 37.
    The American Cancer Society Guidelines for the Prevention and Early Detection of Cervical Cancer. American Cancer Society. Website https://www.cancer.org/cancer/cervical-cancer/prevention-and-early-detection/cervical-c... Last Revised: 9 Dec 2016.
  38. 38.
    Apgar BS, Zoschnick L, Wright TC. The 2001 Bethesda System terminology. Am Fam Physician. 2003;68(10):1992–8.PubMedGoogle Scholar
  39. 39.
    Soloman D. The 1988 Bethesda System for reporting cervical/vaginal cytologic diagnoses: developed and approved at the National Cancer Institute workshop in Bethesda, MD, December 12–13, 1988. Diagn Cytopathol. 1989;5(3):331–4.CrossRefGoogle Scholar
  40. 40.
    Broder S. The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses—Report of the 1991 Bethesda Workshop. JAMA. 1992;267:1892.CrossRefPubMedGoogle Scholar
  41. 41.
    Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2114–9.CrossRefPubMedGoogle Scholar
  42. 42.
    Ali SZ, Cibas ES. The Bethesda System for reporting thyroid cytopathology. Definitions, criteria and explanatory notes. New York: Springer Science; 2010.Google Scholar
  43. 43.
    Nayar R, Wilbur DC, editors. The Bethesda System for reporting cervical cytology. Definitions, criteria, and explanatory notes. 3rd ed. New York: Springer; 2015.Google Scholar
  44. 44.
    Clinical Laboratory Improvement Amendments of 1988 changes resulting from the Taking Essential Steps for Testing (TEST) Act of 2012. http://www.gpo.gov/fdsys/pkg/PLAW-112publ202/pdf/PLAW-112publ202.pdf. TEST Act 2012 Citation: 126 Stat. 1483, Public Law 112–202, Sec. 2.
  45. 45.
    Department of Health and Human Services, Centers for Medicare and Medicaid Services. Clinical laboratory improvement amendments of 1988; final rule. Fed Register. 2003 (Jan 24): 3711 [42CFR493.945] http://wwwn.cdc.gov/clia/regs/subpart_i.aspx#493.945.
  46. 46.
    Darragh TM, Winkler B. Anal cancer and cervical cancer screening: key differences. Cancer Cytopathol. 2011;119(1):5–19.CrossRefPubMedGoogle Scholar
  47. 47.
    Leeds IL, Fang SH. Anal cancer and intraepithelial neoplasia screening: a review. World J Gastrointest Surg. 2016;8(1):41–51.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Chiao EY, Giordano TP, Palefsky JM, Tyring S, El Serag H. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis. 2006;43(2):223–33.CrossRefPubMedGoogle Scholar
  49. 49.
    New York Sate Department of Health AIDS Institute. HIV clinical resource: anal dysplasia and cancer. New York, NY: New York State Department of Health.Google Scholar
  50. 50.
    Chin-Hong PV, Berry JM, Cheng SC, Catania JA, Da Costa M, Darragh TM, et al. Comparison of patient- and clinician-collected anal cytology samples to screen for human papillomavirus-associated anal intraepithelial neoplasia in men who have sex with men. Ann Intern Med. 2008;149(5):300–6.CrossRefPubMedGoogle Scholar
  51. 51.
    Holly EA, Ralston ML, Darragh TM, Greenblatt RM, Jay N, Palefsky JM. Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst. 2001;93(11):843–9.CrossRefPubMedGoogle Scholar
  52. 52.
    Piketty C, Darragh TM, Da Costa M, Bruneval P, Heard I, Kazatchkine MD, et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med. 2003;138(6):453–9.CrossRefPubMedGoogle Scholar
  53. 53.
  54. 54.
    Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis. 2002;35(9):1127–34.CrossRefPubMedGoogle Scholar
  55. 55.
    Salit IE, Lytwyn A, Raboud J, Sano M, Chong S, Diong C, et al. The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening. AIDS. 2010;24(9):1307–13.PubMedGoogle Scholar
  56. 56.
    Palefsky JM, Holly EA, Hogeboom CJ, Berry JM, Jay N, Darragh TM. Anal cytology as a screening tool for anal squamous intraepithelial lesions. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14(5):415–22.CrossRefPubMedGoogle Scholar
  57. 57.
    Damin DC, Caetano MB, Rosito MA, Schwartsmann G, Damin AS, Frazzon AP, et al. Evidence for an association of human papillomavirus infection and colorectal cancer. Eur J Surg Oncol. 2007;33(5):569–74.CrossRefPubMedGoogle Scholar
  58. 58.
    Chuang LC, Chen HC, You SL, Lin CY, Pan MH, Chou YC, et al. Association between human papillomavirus and adenocarcinoma of rectum and recto-sigmoid junction: a cohort study of 10,612 women in Taiwan. Cancer Causes Control. 2010;21(12):2123–8.CrossRefPubMedGoogle Scholar
  59. 59.
    Darragh T, Winkler B. The ABCs of anal-rectal cytology. CAP Today. 2004(May 2004).Google Scholar
  60. 60.
    Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271–8.CrossRefPubMedGoogle Scholar
  61. 61.
    Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247–55.CrossRefPubMedGoogle Scholar
  62. 62.
    Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012;136(10):1266–97.CrossRefPubMedGoogle Scholar
  63. 63.
    Cibas ES, Ducatman BS. Cytology: diagnostic principles and clinical correlates. 4th ed. Philadelphia, PA: Saunders/Elsevier; 2014.Google Scholar
  64. 64.
    Darragh TM, Winkler B, Souers RJ, Laucirica R, Zhao C, Moriarty AT, et al. Room for improvement: initial experience with anal cytology: observations from the College of American Pathologists interlaboratory comparison program in nongynecologic cytology. Arch Pathol Lab Med. 2013;137(11):1550–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of PathologyCooper University HospitalCamdenUSA
  2. 2.Department of PathologyHoward University College of Medicine, Howard University HospitalWashington, DCUSA

Personalised recommendations